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Abstract
Aim This study explores clinical outcome in cytochrome
P450 2C19 (CYP2C19)-related poor metaboliser patients
treated with either clopidogrel or prasugrel after percuta-
neous coronary intervention (PCI) and investigates whether
this could be cost-effective.
Methods and results This single-centre, observational
study included 3260 patients scheduled for elective PCI
between October 2010 and June 2013 and followed for
adverse cardiovascular events until October 2014. Post
PCI, CYP2C19 poor metaboliser patients were treated with
clopidogrel or prasugrel, in addition to aspirin. In total,
32 poor metabolisers were treated with clopidogrel and
41 with prasugrel. The number of adverse cardiovascular
events, defined as death from cardiovascular cause, my-
ocardial infarction, stent thrombosis, every second visit to
the catheterisation room for re-PCI in the same artery, or
stroke, within 1.5 years of PCI, was significantly higher in
the CYP2C19 poor metaboliser group treated with clopi-
dogrel (n = 10, 31 %) compared with the poor metaboliser
group treated with prasugrel (n = 2, 5 %) (p = 0.003).
Costs per gained quality-adjusted life years (QALY) were
estimated, showing that genotype-guided post-PCI treat-
ment with prasugrel could be cost-effective with less than
C 10,000 per gained QALY.
Conclusion This study provides evidence that for
CYP2C19-related poor metabolisers prasugrel may be
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more effective than clopidogrel to prevent major adverse
cardiovascular events after PCI and this approach could be
cost-effective.
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Introduction
Over the last decade, dual antiplatelet therapy with aspirin
and clopidogrel has been considered the gold standard ther-
apy for patients undergoing elective percutaneous coronary
interventions (PCI) in preventing major adverse cardiovas-
cular events (MACE) [1]. However, resistance to clopi-
dogrel is a well-described phenomenon, with 15–30 % of
patients having inadequate platelet inhibition while on ther-
apy [1, 2]. Both clinical factors and genetic polymorphisms
are involved in resistance to clopidogrel [2, 3].
Clopidogrel is a pro-drug that requires biotransforma-
tion to generate an active metabolite involving cytochrome
P450 (CYP) enzymes [4]. It was shown that the CYP2C19
enzyme plays a crucial role in this metabolism [5–7]. Clopi-
dogrel-treated patients carrying at least one reduced-func-
tion CYP2C19 allele were shown to have a significantly
higher risk for MACE, especially stent thrombosis, than
non-carriers [6–9]. These results were confirmed by many
studies and two meta-analyses [2, 10, 11]. At the end of
2010 these findings resulted in a Food and Drug Admin-
istration (FDA) boxed warning advising healthcare profes-
sionals to consider using other antiplatelet medication or
alternative dosing strategies for clopidogrel in CYP2C19
poor metaboliser patients.
Therefore, in September 2010 Catharina Hospital started
to determine the CYP2C19 genotype of patients sched-
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uled for elective PCI in order to identify CYP2C19 poor
metabolisers. At first, poor metabolisers were treated with
clopidogrel. After the FDA boxed warning was placed,
prasugrel was prescribed instead of clopidogrel to the poor
metabolisers, with the goal to reduce the number of MACE.
In this paper the results of this therapy change are presented.
In addition, the cost-effectiveness of genotype-guided post-
PCI treatment is discussed.
Methods
Design, setting and definitions
Between September 2010 and June 2013, patients who were
scheduled for elective PCI at Catharina Hospital in Eind-
hoven were enrolled in this study. Patients with ST-segment
elevation myocardial infarction (STEMI) who received pri-
mary PCI were not included. CYP2C19 genotyping was
performed for all patients. Initially, all patients were treated
with a start-up dose of clopidogrel (300 mg) and, post-PCI,
clopidogrel (75 mg daily) in addition to aspirin (80 mg
daily) was prescribed for at least one year. But since
the FDA boxed warning, gradually only prasugrel (10 mg
daily) instead of clopidogrel was prescribed to CYP2C19
poor metabolisers within 1 to 5 days of PCI, starting in
September 2011. Thereby, two groups of CYP2C19 poor
metabolisers were studied, one group treated with clopi-
dogrel and another with prasugrel. As stent thrombosis
was shown by autopsy to be the cause of death 492 days
after PCI for one of the deceased patients in our study,
all CYP2C19 poor metabolisers were followed for at least
1.5 years after PCI, the last patient until October 2014. For
all CYP2C19 poor metabolisers clinical baseline character-
istics were recorded and the medical history was examined
for cardiovascular events. An adverse cardiovascular event
was defined as death from a cardiovascular cause, myocar-
dial infarction, stent thrombosis, every second visit to the
catheterisation room for re-PCI in the same artery, or stroke.
Stent thrombosis was defined according to Academic Re-
search Consortium (http://circ.ahajournals.org/content/115/
17/2344). For verification of medication prescribed after
PCI, the medical file was consulted or the pharmacy or
general practitioner was contacted.
Blood sampling, genotyping and phenotyping
Blood for genotyping was obtained during scheduled blood
collection immediately before PCI. Genomic DNA was
isolated from the patient’s blood using a commercial DNA
extraction kit (Roche Diagnostics Inc.) and a semi-auto-
matic extraction device, the Magnapure (Roche). CYP2C19
genotyping was performed with real-time polymerase chain
reaction and melting temperature analysis using the Light-
cycler hybridisation DNA master mix (Roche Diagnostics
Inc.) and specific primers and probes for detection of the
CYP2C19*2 and *3 alleles and the *17 allele (TIP-MOL-
BIOL and Sigma-proligo) on the Lightcycler 480 (Roche).
Based on the genotypes, patients with CYP2C19 wild-type
were phenotyped as extensive metabolisers, CYP2C19*2
heterozygote and CYP2C19*3 heterozygote patients as
intermediate metabolisers, CYP2C19*2 homozygotes as
poor metabolisers and CYP2C19*17 homozygotes as ul-
tra-rapid metabolisers. The CYP2C19*17 heterozygote
patients were phenotyped as extensive metabolisers and
CYP2C19*2*17 as intermediate metabolisers.
Data analysis
For the baseline characteristics, variables with a Gaussian
distribution were presented as mean ± standard deviation.
P-values were evaluated by a Chi-squared or Fisher’s exact
test using the SPSS statistics software (IBM), version 19
for statistical analyses.
The cost-effectiveness analysis was based on the low-
discrimination scenario of Kazi and colleagues[12], includ-
ing direct medical costs, induced costs, and acute event
costs, and in addition to stent thrombosis also cardiovascu-




A total of 3260 patients were enrolled in this study of
which 2293 were wild-type, 932 were heterozygotes and
89 homozygotes for the CYP2C19*2 allele. In addition,
6 patients were heterozygotes for the CYP2C19*3 allele,
1121 were heterozygotes for the CYP2C19*17 allele and
175 patients were homozygotes for the CYP2C19*17 allele.
This results in allele frequencies of 17, 0.1 and 22.5 % for
CYP2C19*2, CYP2C19*3 and CYP2C19*17, respectively,
which is in agreement with the allele frequency of a normal
Caucasian population [13].
Cardiovascular events
Although all patients were scheduled for PCI, only 71 poor
metabolisers (CYP2C19*2 homozygote) (80 %) underwent
PCI with stent placement. These 71 poor metabolisers were
subdivided based on the antiplatelet drug used. Initially, 32
poor metaboliser patients were treated with clopidogrel, 35
with prasugrel, 2 with ticagrelor and for 2 patients the drug
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clopidogrel and 1 using prasugrel, medication was changed
after an additional PCI. Therefore, these patients are part of
more than one group. In total, 32 poor metabolisers were
enrolled in the clopidogrel group and 41 poor metabolisers
in the prasugrel group (Fig. 2). In the clopidogrel group,
19 patients did not have an event, 10 patients had an event
within 1.5 years of PCI and for 3 patients this was after more
than 1.5 years. In the prasugrel group, 39 patients did not
have an event and 2 patients had event within 1.5 years of
PCI. No significant difference was observed in the baseline
characteristics of the two groups (Table 1). However, the
difference in number of events between the clopidogrel and
prasugrel group was found to be significant: p < 0.001 for
all events and p = 0.003 for events within 1.5 years of PCI.
All three events that took place more than 1.5 years post-
PCI were diagnosed as chest pain due to in-stent stenosis,
which is not related to the patient’s CYP2C19 genotype.
Fig. 1 Antiplatelet treatment of CYP2C19 poor metabolisers after
PCI with stent placement. The number of patients scheduled for elec-
tive PCI, phenotyped as CYP2C19 poor metabolisers, and who re-
ceived a stent is indicated. Patients were subdivided based on the drug
used for antiplatelet therapy. For 6 patient using clopidogrel, prasugrel
was prescribed after the event, and for one patient treated with pra-
sugrel, ticagrelor was prescribed after the event. PM poor metaboliser,
PCI percutaneous coronary intervention
Fig. 2 Cardiovascular events in the clopidogrel and prasugrel CYP2C19 poor metaboliser group. An event is defined as death, MI, stent throm-
bosis or angina pectoris with additional intervention in the same coronary artery. The difference in number of events between the clopidogrel and
prasugrel group was found to be significant: p < 0.001 for all events and p = 0.003 for events within 1.5 years of PCI
Of the 12 events that took place within 1.5 years of PCI,
9 are categorised as MACE (stent thrombosis, myocardial
infarction, death), 8 in the clopidogrel group and 1 in the
prasugrel group (p = 0.008) (Table 2). There were 6 cases
of stent thrombosis, of which 5 definite and 1 probable. Of
the 5 definite stent thromboses, 4 occurred in the clopido-
grel group and 1 in the prasugrel group. One patient died
of stent thrombosis 492 days after PCI as confirmed by au-
topsy; however, clopidogrel was no longer prescribed at the
time of the event. A myocardial infarction in the coronary
artery with the implanted stent 374 days after PCI, while
the patient was still using clopidogrel, was defined as prob-
able stent thrombosis. Three people died because of stent
thrombosis and one patient died of a probable cardiovas-
cular cause. No major bleeding events were reported for
these CYP2C19 poor metabolisers. No events occurred in
the ticagrelor group but the number of patients using tica-
grelor was too small for comparison and statistical analysis.
Stent thrombosis
Among the MACE, the most evidence for an association
with CYP2C19-related clopidogrel resistance is shown for
stent thrombosis [6, 8–11]. Previously, the increased per-
centage of stent thrombosis for subjects carrying at least one
CYP2C19*2 reduced-function allele compared with non-
carriers were reported [6] and the incidence of stent throm-
bosis was shown to be cumulative according to the number
of CYP2C19*2 alleles [8]. Based on these studies, the
number of stent thromboses for the Catharina study popu-
lation in the event that all patients would have been treated
with clopidogrel was predicted. For poor metabolisers, the
predicted number of stent thromboses was 4 (Table 3), of
which 3 are expected to be CYP2C19-related, which is in
agreement with the number of stent thromboses found in
the present study.
As our results for poor metabolisers are in agreement
with the literature, the same is expected to be the case for
intermediate and extensive metabolisers. The chance to de-
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Age, mean (SD), years 65.2 (10.2) 64.2 (11.1) 0.680
Sex, n (%) Male 22 (69) 30 (73) –
Female 10 (31) 11 (27) 0.680
Race, n (%) Caucasian 32 (100) 40 (98) –
Asian 0 (0) 1 (2) 0.370
Medical history, n (%) Smoker 8 (25) 8 (20) 0.600
Diabetes mellitus 7 (22) 7 (17) 0.630
Hypertension 17 (53) 14 (34) 0.110
Hypercholesterolaemia 9 (28) 16 (39) 0.340
Previous PCI 14 (44) 17 (41) 0.750
Previous MI 14 (44) 22 (54) 0.420
Previous CABG 7 (22) 13(32) 0.350
Pharmacotherapy, n (%) Beta-blocker 23 (72) 34 (83) 0.260
ACE inhibitor 7 (22) 13 (32) 0.350
CABG coronary artery bypass graft, MI myocardial infarction, PCI percutaneous intervention








Myocardial infarction 46 days – No –
412 days – No –
Stent thrombosisa
– 2 days Yes –
4 days – No –
4 days – Yes –
7 days – No –
492 days – Yes Autopsy
Stent thrombosis probablea 374 days – No –
Angina pectorisb
– 451 days No –
70 days – No –
158 days – No –
Unknown 112 days – Yes –
Total number of events 10 2 – –
PCI percutaneous intervention
aAccording to the American Research Consortium Statement
bIncluding an additional intervention in same coronary artery
Table 3 Predicted number of stent thromboses
Patient Stent thrombosis
CYP2C19 phenotype Number Chancea Number CYP2C19-independent CYP2C19-related
EM/UM 2239 0.008 18 18 –
IM 932 0.026 24 7 17
PM 89 0.043 4 1 3




aBased on the percentages of stent thrombosis for subjects carrying at least one CYP2C19*2 allele compared with non-carriers (2.7 % vs. 0.8,
respectively) as described by Mega and colleagues [6], and the cumulative incidence of stent thrombosis according to the number of CYP2C19*2
alleles [8]. In case of CYP2C19 independence it is assumed that the chances for poor metabolisers (PM) and intermediate metabolisers (IM)
are identical to that of extensive metabolisers (EM). The total number of stent thrombosis minus the CYP2C19-independent stent thrombosis is
predicted to be the number of CYP2C19-related stent thrombosis
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velop stent thrombosis for intermediate metabolisers is con-
siderably lower than for poor metabolisers (2.6 % vs. 4.3 %,
respectively), but still higher than for extensive metaboliser
or ultra-rapid metaboliser patients (0.8 %) (Table 3). Be-
cause of the large group of intermediate metabolisers this
is predicted to result in 24 additional cases of stent throm-
bosis of which 17 are CYP2C19-related (Table 3).
Cost-effectiveness
In addition to clopidogrel, prasugrel and ticagrelor can be
used to reduce the rate of thrombotic cardiovascular events
for patients who undergo PCI [14–16] and are even recom-
mended for most patients with acute coronary syndromes
(ACS ) [17, 18]. CYP2C19 is involved in the metabolism
of prasugrel, but it does not play a crucial role [2, 5].
Ticagrelor is a direct drug and its metabolism is indepen-
dent of CYP2C19 activity. However, both agents are much
more expensive than clopidogrel and in most countries these
agents are only reimbursed for ACS.
Based on the latest prices for clopidogrel, prasugrel and
ticagrelor, approximately C 25, C 720 and C 866 per year,
respectively, according to the National Health Care Insti-
tute (Zorginstituut Nederland, https://www.medicijnkosten.
nl/), the pharmaceutical expenses for six different therapy
options for the Catharina study population were compared
(Table 4). Giving prasugrel to all patients would mean
a high increase in pharmaceutical expenses of approxi-
mately C 2,200,000 compared with clopidogrel. A less ex-














2239 C 55,975 C 1,612,080 C 55,975 C 55,975 C 55,975 C 1,938,974
IM 932 C 23,300 C 671,040 C 23,300 C 671,040 C 807,112 C 807,112
PM 89 C 2225 C 64,080 C 64,080 C 64,080 C 77,074 C 77,074
Total pharmaceutical costs C 81,500 C 2,347,200 C 143,355 C 791,095 C 940,161 C 2,823,160
Difference PCa C 2,265,700 C 61,855 C 709,595 C 858,661 C 2,741,660
Costs genotyping (C 83/test) C 0 C 270,580 C 270,580 C 270,580 C 0
Extra costsa C 2,265,700 C 332,435 C 980,175 C 1,129,241 C 2,741,660
Incremental QALYb 0.018 nd 0.033 0.058 0.105
Gained QALYsc 58.68 33.95d 107.58 189.08 342.3
Extra cost/gained QALY C 38,611 C 9792 C 9111 C 5972 C 8010
Clopidogrel: C 25/year, prasugrel: C 720/year, ticagrelor: C 855/year
PM poor metaboliser, IM intermediate metaboliser, EM extensive metaboliser, UM ultra-rapid metaboliser, nd not determined, PC pharmaceutical
costs, QALY quality-adjusted life year, ST stent thrombosis
aCompared with generic clopidogrel
bAccording to Kazi and colleagues [12]
cGained QALY = incremental QALY × number of patients of study population (n = 3260)
dThis option was not determined by Kazi and colleagues; therefore, the gained QALYs were calculated based on the 8 cases of MACE reported
in Table 2 and the estimation that patients aged 65 years having PCI for ACS and being treated with clopidogrel and aspirin for 12 months are
projected to have a life expectancy of 9.428 QALYs over their lifetimes [12]. Three patients could have been prevented from dying, which equals
28.3 QALYs. For the 5 patients who did survive stent thrombosis or myocardial infarction a 12 % permanent quality-of-life decrement is assumed
[12], which equals 5.66 QALYs. Together, it is estimated that 33.95 QALYs could have been gained
pensive alternative is to give prasugrel only to the high-risk
poor metabolisers. This increases the pharmaceutical ex-
penses by just C 60,000, but genotyping is required, result-
ing in an additional C 270,500 (C 83 per test according to
the latest tariffs of the Dutch Healthcare Authority (NZa)).
As intermediate metabolisers also have an increased risk for
MACE while on clopidogrel therapy [10], both the interme-
diate and poor metabolisers could be treated with prasugrel,
preventing all the CYP2C19-related events (Table 3). This
leads to an increase in pharmaceutical expenses of over
C 700,000 and additional costs for genotyping. Because
of the higher drug price, these numbers are even higher for
both the ticagrelor therapy options (Table 4).
Recently, the results of a cost-effectiveness study of
genotype-guided dual antiplatelet therapies for ACS in the
United States were presented [12]. It was concluded that
treatment with prasugrel or ticagrelor for all patients was
relatively expensive, but both genotype-guided therapy with
prasugrel or ticagrelor may be an economically reasonable
alternative for clopidogrel in dual antiplatelet therapy. The
incremental quality-adjusted life years (QALYs) as pre-
sented by Kazi and colleagues [12] were used to calculate
the gained QALYs for the different therapy options pre-
sented above. As expected, the costs per gained QALY
for prasugrel for all patients is high, C 38,611 per gained
QALY (Table 3). But, for genotype-guided prasugrel and
genotype-guided ticagrelor, these costs per gained QALY
are much lower, C 9111 and C 5972, respectively. In
addition, the gained QALY for ticagrelor for all patients
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is also low at C 8010 per gained QALY. This difference
in incremental cost-effectiveness ratio between prasugrel
and ticagrelor was previously explained by the increase of
fatal bleeding when using prasugrel [12, 14, 15]. The costs
per gained QALY for prasugrel for poor metaboliser pa-
tients only, as routinely applied in Catharina Hospital, were
estimated to be C 9792.
Discussion
In this study, based on real-world observations among 3260
elective PCI patients, we found an increased risk for car-
diovascular events in CYP2C19 poor metabolisers treated
with clopidogrel compared with prasugrel. These results
support that CYP2C19 poor metaboliser patients are con-
sidered to be at high risk for recurrent events if treated with
clopidogrel, as previously described [6, 8–11].
In the Netherlands, the mean ‘willingness to pay’ is esti-
mated to be about C 65,000 per QALY based on the Dutch
EQ-5D tariffs and visual analogue scale valuations [19, 20].
Our analysis shows that prasugrel for poor metaboliser pa-
tients only, as routinely applied in the Catharina Hospital,
could be cost-effective. In addition, it is implementable
in daily clinical practice, with relatively low additional
costs, and, in the Netherlands, prasugrel in combination
with acetylsalicylic acid is approved and reimbursed when
prescribed after stent placement, also in case of non-ACS
(https://www.medicijnkosten.nl/).
In addition to the high-risk CYP2C19 poor metaboliser
patients, also the intermediate metabolisers are at increased
risk for MACE [10]. Following the USA [12], our cost-
effectiveness analysis shows that also in the Netherlands,
the genotype-guided prasugrel and genotype-guided tica-
grelor therapy for both CYP2C19 poor metaboliser and in-
termediate metaboliser patients, and even ticagrelor for all
patients could be economically reasonable alternatives for
clopidogrel therapy. These results could help in political
discussions and discussions with health insurance compa-
nies, which may result in changing daily clinical practice
to genotype-guided antiplatelet therapy in future.
Limitations
Although being in line with the literature [6, 8], the number
of events is too small to draw any definite conclusions, em-
phasising the need for further studies to confirm the present
results. Baseline characteristics were comparable between
the clopidogrel and prasugrel group, but the observational
design of the study cannot fully correct for other sources of
bias that may have influenced the results. The switch from
clopidogrel to prasugrel took place within 1 to 5 days of
PCI; however, it is unclear if more events could have been
prevented if prasugrel had been given to the poor metabolis-
ers on the day of PCI. Also, it cannot be excluded that the
use of ‘second-generation stents’ could have influenced the
results [21].
Conclusion
This study provides evidence that for CYP2C19-related
poor metabolisers prasugrel may be more effective than
clopidogrel to prevent major adverse cardiovascular events
after PCI and this approach could be cost-effective.
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